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Abstract 
The chemical identification of new psychoactive substances (NPS) in the field is challenging 
due not only to the plethora of substances available, but also as a result of the chemical 
complexity of products and the chemical similarity of NPS analogues. In this study, handheld 
Raman spectroscopy and the use of two excitation wavelengths, 785 and 1064 nm, were 
evaluated for the identification of 60 NPS products. The products contained a range of NPS 
from classes including the aminoindanes, arylalkylamines, benzodiazepines, and piperidines 
& pyrrolidines. Identification was initially assessed using the instruments’ in built algorithm 
(i.e., % HQI) and then further by visual inspection of the Raman spectra. Confirmatory 
analysis was preformed using gas chromatography mass spectrometry. For the 60 diverse 
products, an NPS was successfully identified via the algorithm in 11 products (18 %) using 
the 785 nm source and 29 products (48 %) using the 1064 nm source. Evaluation of the 
Raman spectra showed that increasing the excitation wavelength from 785 to 1064 nm 
improved this ‘first pass’ identification primarily due to a significant reduction in 
fluorescence, which increased S/N of the characteristic peaks of the substance identified. 
True positive correlations between internet products and NPS signatures ranged from 57.0 to 
91.3 % HQI with typical RSDs < 10 %. Tablet formulations and branded products were 
particularly challenging as a result of low NPS concentration and high chemical complexity, 
respectively. This study demonstrates the advantage of using a 1064 nm source with handheld 
Raman spectroscopy for improved ‘first pass’ NPS identification when minimal spectral 
processing is required, such as when working in field. Future investigations will focus on the 
use of mixture algorithms, effect of NPS concentration, and further improvement of spectral 
libraries. 
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1. Introduction 
In recent years, the use of new psychoactive substances (NPS) has proliferated globally.[1] 
NPS, also known as ‘legal highs’, designer drugs, ‘herbal highs’, ‘bath salts’ and ‘research 
chemicals’, are often perceived as ‘legal’ synthetic recreational drugs with analogous 
pharmacological effects to internationally controlled drugs of abuse.[2] The UK Psychoactive 
Substances Act 2016, recently enacted, defines these substances as ‘capable of producing a 
psychoactive effect in a person who consumes it’.[3] The United Nations Office on Drugs and 
Crimes (UNODC) stated that up to December 2013, over 445 NPS had been reported 
worldwide. In Europe alone, approximately two NPS were notified weekly to the Early 
Warning System (EWS) in 2014.[4] NPS include newly invented compounds (e.g., STS-135), 
revisited research chemicals (e.g., MT-45)[4, 5] diverted pharmaceuticals (e.g., gabapentin), 
products marketed as food supplements (e.g., adrafinil), and resurged controlled drugs of 
abuse (e.g., carfentanyl,  an analogue of the opioid fentanyl)[4] Hence, the term ‘new’ was 
employed to indicate ‘newly misused’ and ‘newly synthesised’ in clandestine laboratories 
rather than simply ‘newly invented’.[6]  
 
The abuse of NPS can result in varied and unpredictable harm as there are no regulations 
concerning content, potency, point of sale and purchase age.[7] This is compounded by the 
facile dissemination via free movement across borders, head shops and easy internet sales. 
They are deceitfully marketed to imply legality and safety[2] and often branded with attractive 
names such as pink champagnes and pink panthers. The abuse of NPS has been linked to 
violence and aggression[8], sympathomimetic symptoms[9],acute organ failure,[10] psychosis[9] 
as well as fatalities.[11] At present, the dearth of pharmacological and toxicological knowledge 
on NPS increases the potential risks and harms to users and greatly impacts treatment 
decisions.[12] The net contribution of NPS abuse to adverse health consequences and crimes is 
still unknown as they are not easily detected using common forensic and toxicology 
screening tests.[13] Thus, the sheer number and chemical variety of NPS along with their 
potential health risks impacts both health and legal authorities.[2] As a result, countries such 
as the UK are taking measures to control these substances,[3] where chemical monitoring will 
be key to achieving this. 
 
The identification and characterisation of NPS to inform risk assessment and drug control 
pose a great analytical challenge. This is again due to the sheer number of NPS, the 
permeations of mixtures that can be concocted with and without adulterants, and the 
continued emergence of new (i.e., unknown) chemical substances. According to the UNODC, 
gas chromatography – mass spectrometry (electron ionisation) (GC-MS (EI)) was the 
predominant analytical technique employed by EU countries for chemical analysis of NPS 
mixtures.[1] For example, this technique has been shown to successfully discriminate between 
NPS classes[14-17] as well as within classes such as cathinones,[18] aminoindanes[19, 20] and 
benzylpiperazines.[21] In circumstances where no reference standards or data were available, 
nuclear magnetic resonance spectroscopy (NMR) has been used to determine the chemical 
connectivity of NPS such as cathinones[22] and aminoindanes.[19, 20] High performance liquid 
chromatography (HPLC) was used with various detectors to separate compounds between 
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NPS classes[16] as well as within classes of cathinones[23] and cannabinoids.[24] In general, the 
techniques mentioned above require transport to a forensic laboratory and solvent 
dissolution/filtering before analysis. In contrast, vibrational techniques such as Fourier 
transform infrared (FT-IR), near infrared (NIR), and Raman spectroscopy can perform rapid 
analysis in the solid-state and are available in handheld and portable versions, which are 
advantageous for in-field testing for law enforcement and healthcare professionals.[25] FT-IR 
has traditionally been a preferred forensic technique due its selectivity and specificity.[18] For 
example, FT-IR was used to discriminate between three different 
trifluoromethylmethcathinone analogues[18] and two methylenedioxypyrovalerone (MDPV) 
isomers.[26] Although FT-IR can be used in the solid-state, analysis through packaging is 
often difficult and interferences from excipients/cutting agents are common. The use of NIR 
spectroscopy for the identification of NPS also shows promise,[27, 28] but NIR is more 
susceptible to moisture effects, physical properties and cutting agents, and often requires 
careful selection of data treatment. The use of Raman spectroscopy may overcome these 
challenges as it offers a number of advantages for in-field testing such as high discrimination 
power,[29] minimal to no sample preparation, through package analysis, and low sensitivity to 
moisture, physical properties[30] and cutting agents.[31] A recent study evaluated the use of 
hand-held FT-IR, NIR and Raman spectrometers for NPS analysis, where Raman 
spectroscopy preformed the best when identifying the components in model mixtures.[31] 
Although the UNODC does not report on the use of Raman spectroscopy for NPS 
characterisation,[1] it is considered a Category A forensic technique.[29] For that reason, 
Raman analysis has been employed in research and forensic analysis[32] for the 
characterisation of drugs of abuse such as 3,4-methylenedioxy-N-methylamphetamine 
(MDMA), cocaine and heroin.[33] More recently, a number of studies have evaluated the use 
of Raman for NPS products.[32, 34-38] Maheux and Copland (2011) used a range of analytical 
techniques including Raman spectroscopy for the identification of cathinones in seized 
samples.[34] Studies also reported on the use of Raman spectroscopy to discriminate between 
cathinone regioisomers[35] and derivatives[32] using benchtop Raman instruments employing a 
laser excitation wavelength (λex) of 785 nm. Bell and coworkers recently reported on the use 
of Raman spectroscopy for the identification of a range of NPS products using an λex of 785 
nm.[38] From these studies, a challenge when using Raman to analyse NPS ‘street samples’ 
was fluorescence, often resulting from impurities and/or cutting agents, which can mask the 
signal from the active ingredients in the product.[31, 39, 40] Goodacre and coworkers 
investigated the use of surface enhanced Raman spectroscopy (SERS) to enhance the Raman 
signal while also reducing interference due to fluorescence.[36, 37] Although SERS is a viable 
approach for fluorescence reduction, careful and invasive sample preparation is often needed. 
An alternative approach which requires no sample preparation is the use of a longer λex (e.g., 
1064 nm) which has been shown to improve identification of traditional drugs of abuse such 
as cocaine and amphetamine.[40, 41] At present there remains limited information on the use of 
hand-held Raman spectroscopy for the wide range of NPS products available and the 
feasibility to improve NPS identification by using a longer λex. 
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The aim of this study was to investigate a wide range of NPS products purchased from the 
internet using handheld Raman spectroscopy and to evaluate the performance of two 
wavelengths, 785 and 1064 nm, for the identification of these substances using a ‘first pass’ 
identification algorithm and further assessment of the Raman spectra. 
2. Experimental 
2.1 Chemicals and Reagents 
The reference standards of eight NPS drugs, eight adulterants and twelve 
cutting agents were used for the study. The NPS reference standards 
(Figure 1) 2-aminoindane (2-AI), 5,6-methylenedioxy-2-aminoindane 
(MDAI), 1-benzofuran-5-ylpropan-2-amine (5-APB), 1-benzofuran-6-
ylpropan-2-amine (6-APB), 1-(thiophen-2-yl)-2methylamino propane 
(MPA), etizolam and methylphenidate (MPD) were purchased from LGC 
standards (Teddington, UK); and dextromethorphan (DXM) was purchased 
from Sigma Aldrich (Dorset, UK). The adulterants benzocaine (BEN), 
caffeine (CAF), lidocaine (LID), paracetamol (PAR), phenacetin (PHE) 
and theophylline (THEO) were purchased from Sigma Aldrich (Dorset, 
UK); diltiazem (DIL) was obtained from the Medicines Testing Lab (UK); 
and procaine (PRO) was obtained from British Drug Houses (London, 
UK). The cutting agents calcium carbonate (CaCO3), creatine (CRE), 
dextrose (DEX), glucose (GLU), lactose (LAC), L-tyrosine (L-TYR), 
magnesium stearate (MGS), microcrystalline cellulose (MCC), 
niacinamide (NIA), sucrose (SUC), talc (TAL) and taurine (TAU) were 
purchased from Sigma Aldrich (Dorset, UK). Sixty NPS products (i.e., 
powders, capsules and tablets) were purchased from the internet (Tables 1-
3), under a Home Office licence, and selected according to their label 
claim and UNODC classification. Additional details for the 60 NPS are 
provided in Table S1 (Supplementary Information). Powders and capsules 
were emptied into clear glass vials (Kimble Chase vial screw thread with 
PTFE cap, China) for Raman analysis, while the tablets were crushed using 
an agate mortar and pestle before transferring into glass vials. The glass 
vials were vortex mixed before collection of each spectrum using a 
VORTEX-GENIE2 (Scientific industries, Inc., USA) mixer for 30 s, 
shaken, then the process repeated. For GC-MS analysis, solutions (1 mg 
mL-1) of each standard and product was prepared in HPLC grade methanol 
from Fisher Scientific (Loughborough, UK), except for the benzodiazepine 
tablets which were concentrated to ca. 45 mg mL-1 and filtered through 0.2 
µm PTFE membrane filters (National Scientific Company, USA) prior to 
analysis.  
 
 
Fig. 1: The 
chemical 
structures of (a) 
2-AI, (b) 5,6-
MDAI, (c) 5-
APB, (d) 6-APB, 
(e) MPA, (f) 
Etizolam (g) 
MPD and (h) 
DXM. 
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2.2 Analysis of NPS and related substances using handheld Raman spectroscopy 
Two handheld Raman instruments with different laser sources, Xantus-1 and First-Guard 
(Rigaku, USA), were employed for the analysis of NPS products. Specifications of both 
instruments are shown in Table S2 (Supplementary Information). Four methods were used to 
collect the Raman spectra depending on the nature of the substance and included method A 
(1000 ms exposure time; 300 mW laser power; 2 accumulations), method B (5000 ms 
exposure time; 490 mW laser power; 2 accumulations), method C (500 ms exposure time; 
200 mW laser power; 2 accumulations), and method D (1000 ms exposure time; 100 mW - 1 
mW laser power; 2 – 25 accumulations). All samples were initially run using method A, but 
method B was used for samples that displayed a poor Raman signal. Method C was used for 
samples that were burned from long exposure time and/or high laser power (i.e., coloured 
samples or samples containing fluorescing chemicals). Method D was developed in an 
attempt to collect Raman signals from challenging samples, which exhibited very high 
fluorescence background and/or burned with method C. This was done by adopting an 
iterative approach to reducing the laser power and increasing the number of accumulations. 
All methods used baseline correction, and the dark background was corrected for every 15 
minutes. The instruments were calibrated each day before analysis using a benzonitrile 
reference standard (Rigaku, US). Most reference standards and products were analysed 
directly through glass vials after optimisation of the vial holder attachment with respect to the 
focal point. For NPS standards that were limited in quantity, 2 mg were placed on aluminium 
foil plates (Fisher Scientific, China) and the signal was optimised using the adjustable probe 
tip. All substances were analysed in triplicate. Raman spectra of the reference substances (n = 
28) were added to the on-board factory spectral library, which was composed of 260+ spectra 
of common chemical substances. For a ‘first pass’ identification, the spectra from the NPS 
products were automatically compared to the on-board reference library and reported a 
percentage hit quality index (% HQI) correlation. The mean ± the standard deviation of the 
highest hit was calculated from the triplicate measurements and reported. If the correlations 
between the triplicate analyses were inconsistent, this was reported instead of a mean value. 
The product spectra were also visually inspected and compared to reference spectra, which 
was also used to evaluate the findings of the matching algorithm. 
2.3 Confirmatory analysis of NPS and related substances using gas chromatography - 
mass spectrometry (GC-MS) 
GC-MS analysis was used to confirm the identity of compounds present in the purchased 
internet products. The analysis was performed using a Varian 240 ion trap MS equipped with 
a Varian 450 gas chromatography instrument and a Varian 8400 auto-sampler from Agilent 
Technologies (Berkshire, UK). Samples were analysed using electron ionization (EI) with a 
scan range of m/z 40 – 1000. An Agilent Technologies column (30 m x 0.25 mm x 0.25 µm) 
coated with a 0.50 mm film of 50% phenyl – 50% methyl polysiloxane was used with helium 
gas as the mobile phase at a flow rate of 1 ml min-1. A CP-1177 injector was held at 275 oC 
and was used in split mode (10:1) for most samples, but in splitless mode when low signals 
were observed. An injection volume of 1µL was used for all samples. The column 
temperature was programmed as follows: 50 oC for 2 min, ramped to 300 oC, 15 oC min-1, 
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held for 5 min, then cooled to 50 oC; the total run time was 28.67 min. The mass spectra 
obtained were compared to the purchased reference standards and the following EI spectral 
libraries: NIST (Version v. 1.0.2.2), SWGDRUG MS (Version 2.1 (2014)) and Cayman 
(Version v. 04292014).  
 
3. Results and Discussion 
3.1. In-built identification method (or instrument algorithm) 
 
Raman responses were initially evaluated using a ‘first pass’ identification algorithm, 
percentage hit quality index (% HQI), which is used to measure the similarity between the 
measured spectrum of an unknown material against library signatures of known references.[42] 
HQI is calculated as shown in Eqn (1) and indicates how much the test spectrum correlates to 
the library signature(s) in %. Unlike raw material identification where the % HQI is 
commonly set between 80 and 99 %, NPS products may contain mixtures of NPS, 
adulterants, and cutting agents, which can result in a lower % HQI, yet still correlating to the 
most prominent substance.[42] The extent of this change in relation to the composition will be 
reviewed. Evaluation of the Raman spectra was carried out and compared to the results of the 
matching algorithm for the NPS reference standards and products.   
HQI = (!"#$%$&  .    !"#"$%")!  ∗!""(!"#$%$&  .    !"#$%$&)(!"#"$%"  .    !"#"!"#)         (Eqn 1) 
3.2.Raman analysis of purchased reference standards 
A number of pure substances (i.e., eight NPS, eight adulterants and 12 cutting agents) were 
purchased as reference standards based on the NPS purchased from the internet. A spectrum 
was collected for each substance and stored in the on-board library. A representative 
spectrum for each NPS reference standard using the 1064 nm source is provided in 
Supplementary Information (Figure S1). When comparing the spectra visually, they all have 
distinctive Raman fingerprints, except for 5 and 6-APB. In this case, the spectra are difficult 
to distinguish, as the chemical structures differ only in the substitution position of the 
alkylamine. In the case of the aminoindane analogues, 2-AI and 5,6-MDAI, the chemical 
structures differ by a methylenedioxy group (Figure 1). Addition of this moiety to the 2-
aminoindane backbone resulted in the appearance of two distinct peaks at 713 and 1350 cm-1 
likely due to the –C=C– cis-di-substituted deformation vibrations and methoxy stretching 
vibration.[43] The spectra for etizolam and MPA each have only one predominant peak at 
1496 and 1438 cm-1 respectively, which may effect the identification of these substances. 
Although MPA, 5-APB, and 6-APB fall under the category of arylalkylamines, the spectrum 
of MPA shows clear differences to the APB isomers’ spectra. MPD, a piperidine, showed 
characteristics peaks 996, 1189, 1431, 1587 and 1723 cm-1. DXM from the ‘other category’ 
showed characteristic peaks at 686, 853, 1245, and 1439 cm-1. To test the accuracy and 
selectivity of each instruments’ algorithm, the standards were run as test samples (NPS 
standard results are presented in Table S3 Supplementary Information). Using the 785 nm 
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source, 27 out of 28 standards were consistent with their library signature with % HQI values 
ranging from 90 ± 10 to 100 %. Microcrystalline cellulose resulted in inconsistent 
correlations to lactose and amylose from potato. The spectra indicated that the mismatch was 
likely the result of a high fluorescent background with minimal peaks seen for all three 
replicates. When using the longer 1064 nm wavelength, 27 out of 28 standards correlated to 
their library signature. Of those, 23 standards were consistent with their library signature with 
% HQIs ranging from 90.0 ± 0.9 to 100.0 ± 0.1 %. Four samples correlated with % HQIs < 
90 % which were 2-AI, 5,6-MDAI, 6-APB and MPA with % HQI ranging from 72 ± 1 to 85 
± 1. The only mismatch for the 1064 nm instrument was for magnesium stearate (MGS). The 
MGS spectrum correlated to the signature of beeswax, a chemically similar compound, as the 
first hit (90 ± 4 % HQI), but correlated to MGS in all measurements as the second hit (80 ± 2 
% HQI). In summary, both instruments showed selectivity for the majority of standards run 
as test samples, including the APB positional isomers. Fluorescence affected one sample 
using the 785 nm, and poor Raman scatterers often gave slightly reduced % HQIs (i.e., 70 – 
90 %) for the 1064 nm. Slight reductions in % HQI for these particular standards were 
perhaps also a consequence of needing to run these standards on Al plates with a small 
sample size. Although an optimisation protocol was followed, variations in the beamwidth 
and distance to the target substance can influence spectral quality effecting the reproducibility 
and % HQI value during validation but also when analysing NPS products.    
3.3.Raman and GC-MS analysis of NPS internet products  
 
The effect of using different λex (i.e., 785 and 1064 nm) for the identification of NPS internet 
products was assessed. In this study, 60 NPS products were analysed using two handheld 
Raman instruments using a ‘first pass’ in-built matching algorithm and evaluation of the 
Raman spectra. The NPS products analysed covered a wide range of categories according to 
the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) classification[44] 
(Table S1, Supplementary Information). GC-MS was employed to confirm the identity of 
volatile/semi-volatile compounds present in the NPS products. 
3.3.1. Aminoindanes 
Twelve aminoindane samples, purchased from the internet, were analysed using both Raman 
instruments and GC-MS (Table 1). Internet products included three of the most popular 
aminoindane substances, 2-AI, 5-IAI and MDAI.[45] Aminoindanes are amphetamine 
analogues and have been shown to be potent serotonin-releasing substances.[45] The GC-MS 
results indicated that 11 out of the 12 products did contain an aminoindane,[20, 46] while only 
nine products contained the aminoindane reported on the label claim. When using the 
standard 785 nm laser, only four of the NPS products (i.e., P6, 8, 9 and 12) correlated to an 
aminoindane substance using the algorithm. These four products correlated to 5,6-MDAI, as 
confirmed by GC-MS, with % HQIs ranging from 60 ± 8 to 84 ± 10. A high fluorescent 
background and low Raman signal were observed for P1, 2, 4, 10 and 11. These products 
correlated to MPA at % HQIs ranging from 96.3 ± 0.8 to 97.0 ± 0.3, but MPA was not 
confirmed using GC-MS except in P11. This was likely the result of the MPA standard 
spectrum (i.e., the spectral library signature) displaying a high fluorescent background 
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(Figure S2 in Supplementary Information). Consequently, the MPA signature correlated 
highly to NPS product spectra with similar backgrounds and little to no Raman bands, 
resulting in the false positives. For example, the Raman spectrum of P11 (Figure 2a) showed 
small peaks at ca. 714, 782 and 864 cm-1, which match Raman bands for 5,6-MDAI, but due 
to the large fluorescent background this sample correlated to MPA at 96.5 ± 0.2 %. As the 
Raman bands for MPA at 1442 cm-1 were not visible, this correlation was likely also a false 
positive. Product 5 and 7 showed some higher intensity Raman peaks on a fluorescent 
background but resulted in no correlations (no match). This may have occurred as the HQI 
algorithm considers fluorescence signals as additional characteristics of the unknown 
sample.[47] Interestingly, whilst P3 was confirmed to contain both 5,6-MDAI and CAF, the 
spectra collected using the 785 nm source correlated to CAF demonstrating the challenge of 
identifying NPS in a complex mixture adulterated with a relatively strong Raman scatterer. 
The 12 samples were then analysed using the 1064 nm source where 9 of the 12 samples (P1, 
2, 5 – 9, 11 and 12) correlated to the NPS present in the sample with HQIs ranging from 60 ± 
6 to 91.3 ± 0.4 %. When using the 1064 nm instrument, fluorescence was significantly 
reduced for many of the products as shown for P11 (Figure 2b). This resulted in improved 
spectral definition and subsequent identification. Figure 3a shows a closer look for two 
examples, 2-AI (P1) and 5,6-MDAI (P11), comparing the NPS reference and product spectra. 
Although the GC-MS data indicated that both 2-AI and 5,6-MDAI were present in P1, the 
Raman peaks consistent with 2-AI (i.e., at 775, 844, 1020, 1205, and 1236 cm-1) dominate the 
spectrum. P11 was also confirmed to contain two NPS, MPA and 5,6-MDAI, where most 
peaks were consistent with 5,6-MDAI such as 713 and 1355 cm-1, however, peaks for MPA 
were also visible at 1038 an 1433 cm-1. It is important to note that two products, P4 and P11, 
contained a combination of MDAI and MPA, which has been reported to have synergistically 
and/or additive effects.[48] In summary, the use of a lower energy wavelength reduced 
fluorescence, which improved signal to noise of discriminating peaks and ‘first pass’ 
identification of the active NPS for 5 of the 12 aminoindane internet products, resulting in a 
total of 9 products with a correctly identified NPS. 
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Table 1: Results from the analysis of aminoindane and arylalkylamine internet products using two handheld 
Raman spectrometers (λex = 785 and 1064 nm) and GC-MS1 
Product       
No. 
Product name Handheld Raman 
785 nm 
Handheld Raman 
1064 nm 
GC-MS 
 
    ID % HQI ID % HQI RT           
(min) 
Base 
Peak 
(m/z) 
MS ID 
Aminoindanes 
1 2-AI 
 
MPA3 96.6 ± 0.4 2-AI 80 ± 4 9.9             
12.6 
133               
160 
2-AI                                                      
5,6-MDAI 
2 2-AI MPA3 96.3 ± 0.8 2-AI 91.3 ± 0.4 9.8 133 2-AI                    
3 5-IAI CAF 87 ± 2 CAF 80 ± 10 12.6                     
14.4 
160                  
194  
5,6-MDAI                                                
CAF 
4 5-IAI MPA3 96 ± 0.7 Benzyl 
Alcohol 
80 ± 2 9.0                         
9.4                       
12.6                           
14.64      
58                 
133                                                  
160                 
86 
MPA                                                  
2-AI                                                     
5,6-MDAI                                                 
NC                       
5 MDAI No match 5,6-MDAI   60 ± 6 12.8 160 5,6-MDAI   
6 MDAI 5,6-MDAI 84 ± 10 5,6-MDAI   80.3 ± 0.2 12.8 160 5,6-MDAI   
7 MDAI No match 5,6-MDAI   80 ± 2 12.7 160 5,6-MDAI   
8 MDAI 5,6-MDAI 60 ± 8 5,6-MDAI   80.7 ± 0.1 12.8 160 5,6-MDAI   
9 MDAI 5,6-MDAI 75 ± 6 5,6-MDAI   80.1 ± 0.5 12.9 160 5,6-MDAI   
10 MDAI MPA3 97.0 ± 0.3 No match 
 
14.0                          
14.4                          
15.2                           
15.5 
192                  
191                  
206                 
177  
NC 
NC           
NC             
NC 
11 MDAI  MPA3 96.5 ± 0.2 5,6-MDAI   64.0 ± 1.8 8.7                         
12.6 
58                
160  
MPA                                                
5,6-MDAI 
12 MDAI 5,6-MDAI 67 ± 4 5,6-MDAI   80 ± 2 12.8 160 5,6-MDAI   
Arylalkylamines 
13 APB  MPA3 95.2 ± 0.4 5-APB 80 ± 2 11.6            
16.4                        
44                
126                  
5-APB                                  
Pyrovalerone2                                         
14 5-APB MPA3 97.2 ± 0.6 5-APB 55.0 ± 0.6 11.6 44 5-APB 
15 5-APB MPA3 94 ± 1 5-APB 60 ± 1 11.4 44 5-APB  
16 5-APB MPA3 95.8 ± 0.7 No match 11.7 44 5-APB  
17 5-APB MPA3 95.1 ± 0.1 Data acquisition failed 11.8                          
12.3 
44                  
134 
5-APB                                               
5-APDB2 
18 6-APB Inconsistent correlations MCC 77.4 ± 0.2 11.6 44 5-APB  
19 6-APB Inconsistent correlations 
 
6-APB 50 ± 3 11.4                          
11.7                       
12.9  
44                  
44               
160 
5-APB                                              
6-APB                                                 
5,6-MDAI 
20 5-MAPB Inconsistent correlations 5-APB 60 ± 4 12.1 58 5-MAPB2 
21 MPA MPA3 94 ± 2 MPA 82.9 ± 0.7 9.1                       
16.6 
58                       
271 
MPA                                        
DXM 
22 MPA MPA3 98.1 ± 0.2 MPA 60 ± 2 9.2 58 MPA 
23 MPA MPA3 97.2 ± 0.1 MPA 78.2 ± 0.8 8.8            
11.9                    
12.0                     
14.4                     
17.4 
58                               
58                         
44                        
194                        
110 
MPA                                             
NC                                                         
6-APB                                                                                                                                                                                                                         
CAF                                               
5-MeO-DALT2 
24 MPA MPA3 98.1 ± 0.2 MPA 81.2 ± 0.8 8.8 58 MPA 
25 MPA MPA3 96 ± 1 MPA 80 ± 2 8.7 58 MPA 
26 MPA MPA3 96 ± 3 MPA 80 ± 2 8.8 58 MPA  
1ID: identification; RT: retention time; NC: not confirmed 
2Raman spectrum of substance not present in both Raman libraries 
3Suspected false positive 
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Fig. 2: Raman spectra of selected NPS internet products using the 785 nm (a) and 1064 nm (b) excitation 
wavelength. The products analysed were P11, P23, P27, P39, P43, and P53 with the label claim of MDAI, 
MPA, Etizolam, EPD, DXM, and Pink Champagnes, respectively, which does not necessarily represent the 
sample composition. The spectra presented have been normalised to the maximum peak. 
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3.3.2. Arylalkylamines 
 
Fourteen arylalkylamines samples, purchased from the internet, were analysed using both 
Raman instruments and GC-MS (Table 1). These included the aminopropylbenzofurans 
(APB) isomer/analogues 5-APB, 6-APB and 1-(Benzofuran-5-yl)-N-methylpropan-2-amine 
(5-MAPB). Methyl aminopropamine (MPA) products, reported to exert stimulant effects,[48] 
were also investigated. The GC-MS results showed that all 14 products contained an 
arylalkylamine,[46, 49] while 13 products contained the arylalkylamine reported on the label 
claim. When using the standard 785 nm laser, most samples (i.e., P13 – 17 and P21 - 26) 
correlated to MPA (94 ± 2 to 98.1 ± 0.2 % HQI) while three (i.e., P18 - 20) resulted in 
inconsistent correlations. Upon investigation of the spectra (e.g., see Figure 2a for spectra of 
P23), all samples showed a high degree of fluorescence with little to no distinct Raman bands 
indicating false positive correlations to the MPA signature. Therefore, after visual inspection 
it was suggested that no true positive correlations to an arylalkylamine were found in any of 
the 14 products using the 785 nm source. The 14 products were then analysed using the 1064 
nm source where 10 products (i.e., P13-15, 19, 21-26) correlated to the NPS present in the 
sample with HQIs ranging from 50 ± 3 to 82.9 ± 0.7 %. Again, a reduction in fluorescence 
improved signal to noise of peaks and thus ‘first pass’ identification of the NPS samples. The 
spectra from the NPS that correlated to MPA using an λex of 1064 nm showed a distinct peak 
around 1442 cm-1 with no fluorescence indicting true positive correlations (e.g., see Figure 2b 
for spectra of P23). Figure 3b compares the reference and product spectra for two examples, 
MPA (P23) and 5-APB (P13). As mentioned previously, MPA has only one strong peak with 
other minor peaks, which has been useful for the identification of P23 in this case as no other 
notable peaks are visible. For the Raman spectrum of P13 most peaks could be attributed to 
5-APB (i.e., 758, 1258, 1326, and 1530 cm-1); the spectrum correlated to 5-APB at 80 ± 2 % 
HQI. In regards to the APB analogues, their Raman spectra are very similar as they only 
differ in the substitution position of the alkylamine, however a key discriminating peak can 
be observed at 1350 cm-1 for 6-APB and then slight peaks shifts seen at ca. 1110, 1430 and 
1600 cm-1 (Figure S1 in Supplementary Information). There was a correlation to MCC (77.4 
± 0.2 %) for P18 even though 5-APB was present in the sample, this suggests that the cutting 
agent concentration was in a higher proportion compared to the active ingredient.[31] In the 
case of P20, a 60 ± 4 % correlation to 5-APB was found as no 5-MAPB signature was present 
in the Raman library. This demonstrates that a substance may be correlated to a similar 
structural analogue using the algorithm, which can assist with identifying suspect NPS. 
Samples P16 and 17 resulted in ‘no match’ and failed data acquisition due to sample burning, 
even when using low power, as they were both of a dark colour.[30] The use of a lower energy 
laser wavelength reduced fluorescence from both the cutting agents present and coloured 
samples improving ‘first pass’ identification of the NPS ingredient for 11 of 14 
arylalkylamines products.  
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Fig. 3: Raman spectra of selected products and associated reference spectra from the aminoindane (a), 
arylalkylamine (b), benzodiazepine (c), piperidine & pyrrolidine (d), other (e), and branded product (f) 
categories using a 1064 nm excitation wavelength. Product numbers and reference names are labelled on the 
spectra. The spectra presented have been normalised to the maximum peak. 	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3.3.3. Benzodiazepines 
Nine benzodiazepine (BZD) samples, purchased from the internet, were analysed using both 
Raman instruments and GC-MS (Table 2). The products included two different BZDs, 
etizolam and pyrazolam. Benzodiazepines are pharmaceuticals, which exert depressant, 
anxiolytic, hypnotic and muscle relaxant effects. Due to the high level of excipients present in 
the tablet/pellet formulation, it was necessary to remove the coating and increase the 
concentration of the analysis solution (ca. 45 mg mL-1) to enable detection of the NPS via 
GC-MS. Both etizolam and pyrazolam were then identified in all nine samples using GC-MS. 
Interestingly, P30 and 32 shared three active ingredients despite being purchased from 
different websites and having a different appearance, suggesting a similar supply chain. 
When using the standard 785 nm laser no correlations to a BZD were found in any of the nine 
samples even those samples which were confirmed to contain a BZD via GC-MS. Pyrazolam 
was not present in the Raman libraries but the products were included to investigate analogue 
selectivity. However, P30, 32 and 33 - 35 correlated to the cutting agents LAC (87 ± 5 to 91 
± 5 %) and MCC (83 ± 3 to 87 ± 2 %), respectively. High fluorescent backgrounds occurred 
for four samples (i.e., P27 – 29 and 31), which again resulted in false positive correlations to 
MPA (96.9 ± 0.4 to 98.5 ± 0.7 %) as the 1438 cm-1 characteristic peak was not visible in the 
spectra. Using the 1064 nm source, no correlations to a BZD resulted for any of the nine 
samples. However, P30, 32 and 33 - 35 correlated to the same cutting agents as found with 
the 785 nm source with similar % HQIs. Due to reduced fluorescence, P27 – 29 correlated to 
MCC (70 ± 1 to 70 ± 9 %). For example Figure 2 demonstrates this reduction in fluorescence 
comparing the two wavelength sources with P27. The subsequent identification of MCC is 
better illustrated in Figure 3c using P27 and 33 where the MCC signature is clearly visible 
when comparing it with an MCC reference (c.a., 397, 1094, and 1355 cm-1). For P27, the 
strong signature peak of etizolam at 1496 cm-1 (Figure S1 in Supplementary Information) is 
clearly not visible. As mentioned above both MCC and LAC do not readily dissolve in 
methanol and have low volatility; hence, it is often not detected with GC-MS analysis, but 
may still be present in the sample. Microcrystalline cellulose (MCC) is a common diluent 
used in pharmaceutical tablets and LAC is commonly used in direct compression tableting 
applications and is also used as a tablet filler and binder. As most of the BZD products were 
in tablet or pellet form, the presence of these excipients in high concentration is likely. 
Products 27, 28 and 29 were purchased from three different websites (Table S1); however, 
the three batches, all turquoise in colour, have been shown to contain MCC and etizolam 
using the 1064 nm Raman spectrometer and GC-MS, respectively. This may indicate that 
despite being sold on different websites and compressed with different tablet dies, the powder 
mix could have come from the same supplier. In summary, no NPS ingredients were 
identified in the BZD products using the ‘first pass’ algorithm or by visual inspection of the 
spectra as the products were largely composed of excipients used for tablet and pellet 
construction (i.e., MCC and LAC), which was also observed in a recent study using a 
benchtop Raman spectrometer.[38] This indicates that for these BZDs and perhaps other NPS 
in tablet form, identification of the active ingredient can be challenging (i.e., resulting in false 
negatives), as the amount of active ingredient may be significantly lower relative to the 
excipients. The use of spectral subtraction is a possible tool for mixtures that may reduce 
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these types of false negatives; it could be used to improve the identification of NPS with low 
content in the presence of larger amounts of cutting agents that results in a larger Raman 
signal than the NPS.[38] 
 
Table 2: Results from the analysis of benzodiazepine, piperidine and pyrrolidine, plants and extracts and other 
internet products using two handheld Raman spectrometers (λex = 785 and 1064 nm) and GC-MS1 
Product       
No. 
Product 
name 
Handheld Raman 
785 nm 
Handheld Raman 
1064 nm 
GC-MS 
    ID % HQI ID % HQI RT            
(min) 
Base 
Peak 
(m/z) 
MS ID 
Benzodiazepines 
27 Etizolam MPA3 96.9 ± 0.4 MCC 70 ± 1 23.1 342 Etizolam 
28 Etizolam MPA3 97.49 ± 0.05 MCC 70 ± 4 23.2 342 Etizolam 
29 Etizolam MPA3 96.9 ± 0.7 MCC 70 ± 9 23.2 342 Etizolam 
30 Etizolam LAC 87 ± 5 LAC 80 ± 7 16.9                           
19.3                          
22.9                      
23.2 
339                        
359                            
270                             
342 
JWH-0222                                             
AM-22012                                                  
1-NI2,4                  
Etizolam 
31 Etizolam MPA3 98.5 ± 0.7 Phospho-
rous 
60 ± 3 23.1 342 Etizolam 
32 Etizolam LAC 91 ± 5 LAC 88.6 ± 2.3 16.7                           
21.8                     
22.9                     
23.2 
339                            
268                            
270                             
342 
JWH-0222                                                 
1-N-2-MI2,4                
1-NI2,4                      
Etizolam  
33 Pyrazolam  MCC 86 ± 2 MCC 80 ± 6 13.5 353 Pyrazolam2 
34 Pyrazolam  MCC 87 ± 2 MCC 90 ± 2 13.5 353 Pyrazolam2 
35 Pyrazolam  MCC 83 ± 3 MCC 81 ± 3 13.5 353 Pyrazolam2 
Piperidines & pyrrolidines 
36 Ethyl 
phenidate  
MPD 64 ± 4 MPD 76.6 ± 0.4 14 84 MPD 
37 Ethyl 
phenidate  
MPD 65 ± 2 MPD 76.8 ± 0.4 14 84 MPD 
38 Ethyl 
phenidate  
Inconsistent correlations 
 
No match 
 
19.4 359 AM-22012 
39 Ethyl 
phenidate  
Cetyl-
pyridinium 
chloride 
61 ± 20 MPD 80 ± 2 14 84 MPD 
40 Ethyl 
phenidate  
MPD 63 ± 5 MPD 76.6 ± 0.2 14 84 MPD 
41 Ethyl 
phenidate  
Inconsistent correlations 
 
No match 
 
19.4 359 AM-22012 
Plants and Extracts 
42 LSA 
Morning 
Glory Seeds 
MPA3 96 ± 2 No match 
 
No match 
 
 
Other 
43 DXM Talc 69 ± 3 CAF 80 ± 10 14.4                      
14.8 
194                        
190 
CAF                                                
MXE2 
44 DXM  Inconsistent correlations DXM 60 ± 9 16.6 271 DXM 
45 DXM  DXM 57 ± 1 DXM 64.0 ± 0.4 16.6 271 DXM 
46 DXM  DXM 59 ± 6 DXM 63.8 ± 0.4 16.6 271 DXM  
47 DXM DXM 84.1 ± 0.2 DXM 90 ± 4 16.6 271 DXM 
1ID: identification; RT: retention time; NC: not confirmed 
2Raman spectrum of substance not present in both Raman libraries 
3Suspected false positive 
41-NI: 1-Naphthoyl indole; 1-N-2-MI: 1-Naphthoyl-2-methyl indole       
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3.3.4. Piperidines & pyrrolidines 
Six ethylphenidate (piperidine) samples, purchased from the internet, were analysed using 
both Raman instruments and GC-MS (Table 2). Ethylphenidate (EPD) is a synthetic analogue 
of MPD and was encountered at EU level and in the UK for the first time in 2011.[50] The 
GC-MS analysis confirmed the presence of MPD[51] in four products (i.e., P36, 37, 39 and 
40). Until recently, EPD was uncontrolled in the UK, perhaps a reason why the controlled 
substance MPD was substituted for EPD in these samples. These products are an example of 
how NPS may be marketed as ‘legal’ products, where in fact they contain a controlled drug. 
Thus, only MPD was added to the Raman libraries as EPD was not identified via GC-MS. 
Products 38 and 41 were purchased from the same website and a similar active ingredient 
was identified using GC-MS (i.e., AM-2201). When using the standard 785 nm laser, P36, 37 
and 40 correlated to MPD (63 ± 5 to 65 ± 2 %). Products 38 and 41 showed inconsistent 
Raman responses due to high fluorescent backgrounds. The Raman spectra of P39 correlated 
to cetylpyridinium chloride (61 ± 20 %) where very weak Raman signals were observed on 
top of a high fluorescence background (Figure 2a), again suggesting a false positive. Using 
the 1064 nm source, four of the six samples (i.e., P36, 37, 39 and 40) correlated to MPD, the 
analogue of EPD, with a % HQI of 76.6 ± 0.2 to 80 ± 2. Figure 2b displays the Raman 
spectra of P39 after using the longer wavelength reducing fluorescence. The spectra of two 
products, P39 and 40, compared to the MPD signature shows distinct peaks at 1029, 1180, 
1428 and 1588 cm-1 (Figure 3d) which correspond to Raman bands for the MPD signature 
(Figure S1in Supplementary Information). Products 38 and 41 resulted in ‘no match’ using 
the algorithm, however Raman bands at 511, 668, 775, 1012, 1370, 1516 and 1622 cm-1  
corresponded to peaks for the AM-2201 reference spectra (unpublished work). In summary, 
the 785 nm source successfully identified the NPS ingredient in three products, while use of 
the 1064 nm source reduced fluorescence and improved ‘first pass’ NPS identification for 
one of the three remaining products in addition to evidence for the presence of AM-2201 in 
two products.  
3.3.5. Plants and Extracts 
LSA morning glory seeds (P42) were purchased from the internet and analysed using both 
Raman instruments and GC-MS. Morning glory seeds are known to be sacred seeds, 
originally used by some Mexican Indian tribes. They contain lysergic acid amide (LSA), 
which is the non-alkylated amide analogue of the schedule I controlled lysergic acid diethyl 
amide (LSD).[52] As these samples were seeds, before analysis they were ground using an 
agate mortar and pestle. LSA morning glory seeds were characterised using the black shell 
and grey content. Using GC-MS, the content of the seeds was not identified as no 
chromatographic peaks were observed. When using the standard 785 nm laser, P42 correlated 
to MPA (96 ± 2 %) as seen with other products using the 785 nm laser. However, this is 
again a potential false positive result as the content was not confirmed using GC-MS. Using 
the 1064 nm source, no match was found and the sample was burned upon analysis using all 
methods. Seed samples such as these, which are dark in colour, are particularly problematic 
when analysing via Raman even with the 1064 nm wavelength. 
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3.3.6. Other 
Five DXM samples, purchased from the internet, were analysed using both Raman 
instruments and GC-MS (Table 2). Dextromethorphan (DXM) has been classified as ‘other’ 
in the UNODC (2014) report.[53] DXM is a non-opioid anti-tussive drug and is the d-isomer 
of the codeine analogue levorphanol. It inhibits the re-uptake of serotonin at therapeutic 
doses.[54] The GC-MS analysis identified DXM[55] in four of the five products (i.e., P44 – 47). 
When using the standard 785 nm laser, correlations to DXM were found in three of the five 
samples (P45 – 47) with % HQIs ranging from 57 ± 1 to 84.1 ± 0.2 %. Product 43 correlated 
to TAL (69 ± 3 %) (Figure 2a) and P44 resulted in inconsistent correlations; these spectra 
showed Raman signals on top of slightly fluorescent backgrounds. Using the 1064 nm source, 
four of the five samples (i.e., P44 - 47) correlated to the NPS on the label (DXM) with an 
HQI of 60 ± 9 to 90 ± 4 %. A reduction in fluorescence was most noticeable for P43 (Figure 
2b) which correlated to the unclaimed adulterant CAF at a % HQI of 80 ± 10 %. Figure 3e 
shows an example of two products’ spectra, P43 and 47, and their similarity to the highest 
correlation signature spectrum. The spectra for P43 and CAF are very similar with notable 
peaks at 549, 1325, 1600 and 1690 cm-1 even though MXE was also identified using GC-MS; 
and the spectra for P47 and DXM are also very similar with notable peaks at 686, 852, 1242, 
and 1436 cm-1. In summary, the 785 nm source successfully identified the NPS ingredient in 
three products, while use of the 1064 nm source reduced fluorescence and improved NPS 
identification for one of the two remaining products using the ‘first pass’ identification and 
visual inspection of the spectra  
3.3.7. Branded products 
Thirteen branded products, purchased from the internet, were analysed using both Raman 
instruments and GC-MS (Table 3). Internet products are often branded with names such as 
blast, bliss, bloom and blow.[35] Although these products are marketed with brand names, 
most branded products in this study did have a label claim stating ingredients except for P48 
and 59. The analysis using GC-MS identified seven different NPS substances (Table 3). 
Interestingly, both P23 labelled as MPA and P59 labelled as Route 56 were purchased from 
the same website and shared four active ingredients (i.e., MPA, 6-APB, CAF and 5-MeO-
DALT), again suggesting a similar supply chain. When using the standard 785 nm laser, ‘first 
pass’ correlations to a NPS substance were found for 8 out of 13 samples, even though all but 
one sample was confirmed to contain an NPS via GC-MS. However, for seven of these 
products (i.e., P49 – 55 and 57 – 60) the spectra showed very high fluorescent backgrounds 
resulting in either a false positive correlation to MPA (92.5 ± 0.4 to 99.1 ± 0.1 %) (e.g., see 
Figure 2a for spectrum of P53) or an inconsistent correlation. The calculation of the HQI 
algorithm has been shown to be affected by background fluorescence in unknown spectra, 
depicting slope and offset as differences from library spectra.[47] Pink panthers (P56) 
correlated to 5,6-MDAI with a % HQI of 80 ± 7, whereas the product Blow (P48) correlated 
to BEN with a % HQI of 76 ± 10. Using the 1064 nm source, two additional NPS, MPA (80 
± 2 %) and delta 9-THC (59.3 ± 0.8 %), were identified in P56 and 60. The presence of MPA 
was confirmed using GC-MS, however delta 9-THC could potentially be a false positive 
result, since 9-THC was not identified by the MS libraries. Figure 2b shows the improved 
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Raman spectra of P53 after using the 1064 nm source where clear distinct Raman bands are 
visible. The improved Raman spectra still resulted in ‘no match’ using the algorithm, 
however characteristic peaks for CAF (e.g., 549 and 1322 cm-1) and 2-AI (e.g., 775, 844, and 
1030 cm-1) were clearly visible. Jones et al. evaluated Raman spectra of NPS mixtures by 
subtracting the spectra of pure substances sequentially after identifying the substances using a 
Raman microscope.[38] Interestingly, the product Pink panthers (P56), which was confirmed 
to contain both 5,6-MDAI and MPA with GC-MS analysis correlated to 5,6-MDAI using the 
785 nm source and to MPA using the 1064 nm source. This may be the result of mixture 
heterogeneity inherent to branded products, despite efforts to vortex mix. Figure 3f shows 
peaks in the Raman spectrum for P56 corresponding to those of primarily MPA, i.e., 595, 
677, 810, 1052, and 1436 cm-1; peaks corresponding to 5,6-MDAI are not observed. In 
summary, the ‘first pass’ identification of branded NPS products was very challenging using 
both handheld Raman instruments resulting in many inconsistent correlations, ‘no match’ 
founds, and false positive matches to MPA. This was due mainly to high fluorescent signals 
using the 785 nm, which was significantly reduced using the 1064 nm source, and the 
chemical complexity of the samples. A mixture algorithm or spectral subtraction would be 
useful for these types of samples to improve ‘first pass’ identification as peaks were 
identified which were consistent with NPS reference spectra.   
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Table 3: Results from the analysis of branded internet products using two handheld Raman spectrometers (λex = 
785 and 1064 nm) and GC-MS1 
Product       
No. 
Product 
name 
Handheld Raman 
785 nm 
Handheld Raman 
1064 nm 
GC-MS 
 
    ID % HQI ID % HQI RT           
(min) 
Base 
Peak 
(m/z) 
MS ID 
Branded products 
48 Blow BEN 76 ± 10 BEN 90 ± 7 12.4                          
14.1 
120                      
84 
BEN                                            
MPD   
49 Blurberry MPA3 99.1 ± 0.1 No match 
 
9.5                       
14.4 
133                          
194 
2-AI                                                  
CAF 
50 High beams  MPA3 97.7 ± 0.1 No match 
 
9.4                        
14.4 
133                         
194 
2-AI                                                  
CAF 
51 Magic Beans MPA3 92.5 ± 0.4 Inconsistent correlations 9.4                          
14.4 
133                       
194 
2-AI                                                  
CAF 
52 Pink 
Champagnes  
MPA3 98.0 ± 0.4 Inconsistent correlations 9.4                        
14.4 
133                         
194 
2-AI                                                  
CAF 
53 Pink 
Champagnes  
MPA3 98.4 ± 0.2 No match 9.2                         
14.4        
133                        
194 
2-AI                                                  
CAF 
54 Pink 
Champagnes  
MPA3 98.4 ± 0.1 CAF 54.2 ± 0.2 9.4                        
14.4 
133                         
194 
2-AI                                                  
CAF 
55 Pink 
Champagnes  
MPA3 98.3 ± 0.2 Phospho-
rous 
70 ± 3 9.3                       
14.5 
133                          
194 
2-AI                                                  
CAF 
56 Pink panthers 5,6-MDAI 80 ± 7 MPA 80 ± 2 8.9                        
12.7 
58                       
160 
MPA                                              
5,6-MDAI  
57 Punk plus  Inconsistent correlations L-TYR  54.7 ± 0.7 10.7                     
14.4 
106                         
194 
NIA                                               
CAF  
58 Recovery  Inconsistent correlations Data acquisition failed 7.1 71 No match 
59 Route 56 Inconsistent correlations MCC 60 ± 6 8.8             
11.6              
14.0                
14.4                   
17.3 
58                            
44                            
84                         
194                         
110 
MPA                                                      
6-APB                                               
MPD                                                      
CAF                                                          
5-MeO-
DALT2 
60 White Pearls  Inconsistent correlations 
 
Delta 9-
THC 
59.3 ± 0.8 12.3                      
14.4 
44                      
194 
5-APDB2                                              
CAF  
1ID: identification; RT: retention time; NC: not confirmed 
2Raman spectrum of substance not present in both Raman libraries 
3Suspected false positive 
 
 
4. Conclusion 
In this study, handheld Raman spectroscopy with two excitation sources was used to identify 
NPS in internet products using a ‘first pass’ matching algorithm as well as visual inspection 
of Raman spectra. The ‘first pass’ algorithm approach successfully identified an NPS in 29 
out of 60 (48%) diverse and chemically complex internet products using a 1064 nm laser 
source. An overview of the results is presented in Table 4. An increase in the laser excitation 
wavelength from 785 to 1064 nm improved positive NPS ‘first pass’ identification (i.e., from 
11 to 29 substances). Visual inspection of the spectra indicated that these improvements were 
mainly the result of reduced fluorescence, most likely originating from cutting agents and 
coloured constituents composing the products. Correlations between the internet products 
with the NPS signatures, that were confirmed with GC-MS, ranged from 57.0 to 84.1 % HQI 
with typical RSDs < 10% using the 785 nm source and from 60.0 to 91.3 % HQI with typical 
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RSDs < 7% using the 1064 nm source. Thus, reduced matching algorithm thresholds may be 
required when monitoring NPS products in the field. A higher number of false positives and 
false negative were observed when using the 785 nm source, again resulting mainly from the 
dominant fluorescent background with no notable Raman bands produced by these samples. 
False negatives observed for both wavelength sources were also due to low NPS 
concentration and/or high chemical complexity of the product. For example, no etizolam 
Raman bands were observed for the tablet and pellets as they were largely composed of 
common excipients with a relatively low etizolam concentration. Chemically complex 
samples, such as some of the ‘branded products’, did not correlate to an NPS signature using 
the ‘first pass’ identification but did showed marked improvement in the Raman spectra upon 
using the 1064 nm source where characteristic Raman bands of the references were observed. 
In these cases spectral subtraction could be used to further assist identification. Handheld 
Raman spectroscopy employing a 1064 nm laser source has shown promise for the chemical 
identification of NPS products in the field; in particular, for NPS samples that are highly 
fluorescent. Future work employing a 1064 nm source should focus on further parameter 
optimisation, spectral processing and investigating mixture algorithms with improved NPS 
libraries. 
 
Table 4:	    A summary of the results obtained for NPS identification using the handheld Raman spectrometers      
(λex = 785 and 1064 nm)1 
Category λ ex 785 nm λ ex 1064 nm 
Identification of NPS 11 29 
Identification of adulterant 2 4 
Identification of cutting agent2 7 14 
Fluorescence 38 0 
Inconsistent correlation  10 2 
No match 2 7 
False positive for an NPS  28 1 
False negative for an NPS  46 28 
1Raman spectrometers were used with set parameters as stated in the method section 
2Cutting agents were not confirmed via GC-MS 
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